Enrocare Injection 50Mg/Ml 100Ml

Target species Cattle (calves) Pigs weighing more than 25kg Dogs and cats Indications for use, specifying the target species Calves Treatment of infections of the respiratory tract caused by enrofloxacin susceptible strains of Pasteurella multocida, Mannheimia haemolytica and Mycoplasma spp. Treatment of infections of the alimentary tract caused by enrofloxacin susceptible strains of Escherichia coli. Treatment of septicaemia caused by enrofloxacin susceptible strains of Escherichia coli. Treatment of acute mycoplasma-associated arthritis due to enrofloxacin susceptible strains of Mycoplasma bovis. Pigs Treatment of infections of the respiratory tract caused by enrofloxacin susceptible strains of Pasteurella multocida, Mycoplasma spp. and Actinobacillus pleuropneumoniae. Treatment of infections of the alimentary tract caused by enrofloxacin susceptible strains of Escherichia coli. Treatment of septicaemia caused by enrofloxacin susceptible strains of Escherichia coli. Dogs Treatment of infections of the alimentary, respiratory and urogenital tracts (including prostatitis, adjunctive antibiotic therapy for pyometra), skin and wound infections, otitis (externa/media) caused by enrofloxacin susceptible strains of Staphylococcus spp., Escherichia coli, Pasteurella spp., Klebsiella spp., Bordetella spp., Pseudomonas spp. and Proteus spp. Cats Treatment of infections of the alimentary, respiratory and urogenital tracts (as adjunctive antibiotic therapy for pyometra), skin and wound infections, caused by enrofloxacin susceptible strains of, e.g.: Staphylococcus spp., Escherichia coli, Pasteurella spp., Klebsiella spp., Bordetella spp., Pseudomonas spp. and Proteus spp. Contraindications Do not use in cases of resistance against other fluoroquinolones, due to the potential for cross-resistance. Do not use in dogs under 1 year of age as damage to the articular cartilage may occur during the period of rapid growth, specifically in large breeds of dog. As a precaution very large breeds of dog should not be treated with the product until they are 18 months of age because of their longer growth period. Do not use in cats less than 8 weeks of age. Do not use in case of hypersensitivity to the active substance or to any of the excipients. Do not use in growing horses because of possible deleterious damage on articular cartilage. Special warnings for each target species Cattle and pigs None. Dogs None. Cats Retinotoxic effects including blindness can occur when the recommended dose is exceeded. Special precautions for use Special precautions for use in animals Do not use for prophylaxis. Do not exceed the recommended dosage. Repeat injections should be made at different sites. Do not use in dogs and cats with CNS disturbances. Degenerative changes of articular cartilage were observed in calves treated orally with 30 mg enrofloxacin/kg bw during 14 days. The use of enrofloxacin in growing lambs at the recommended dose for 15 days caused histological changes in the articular cartilage, not associated with clinical signs. Official and local antimicrobial policies should be taken into account when the product is used. Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials. Whenever possible, fluoroquinolones should only be used based on susceptibility testing. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential for cross resistance. Special precautions to be taken by the person administering the veterinary medicinal product to animals This product is an alkaline solution. Wash any splashes from skin and eyes immediately with water. People with known hypersensitivity to (fluoro)quinolones should avoid contact with this product. Do not eat, drink or smoke whilst using the product. In case of accidental self-injection seek medical advice immediately and show the package leaflet or label to the physician. Adverse reactions (frequency and seriousness) Occasionally skin reactions have been seen after administration to kennelled greyhounds. Local tissue reactions may occur at the injection site. Normal sterile precautions should be taken. Use during pregnancy, lactation or lay There is no restriction on the use of this product during pregnancy and lactation. Interaction with other medicinal products and other forms of interaction Care should be taken during the concomitant use of flunixin and enrofloxacin in dogs to avoid adverse drug reactions. The decrease in drug clearances as a result of co-administration of flunixin and enrofloxacin indicates that these substances interact during the elimination phase. Thus, in dogs, the co-administration of enrofloxacin and flunixin increased the AUC and the elimination half-life of flunixin and increased the elimination half-life and reduced the Cmax of enrofloxacin.